New combo aims to make resistant prostate cancer vulnerable to radiation

NCT ID NCT06145633

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This phase 2 trial tests whether adding vorinostat to the radioactive drug 177Lu-PSMA-617 can help men with PSMA-low metastatic castration-resistant prostate cancer. The goal is to increase PSMA levels on cancer cells so the radiation therapy works better. About 15 participants will receive both drugs and be monitored for response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vorinostat and 177Lu-PSMA-617
What this could lead to: If successful, this combination could help more men with PSMA-low prostate cancer benefit from targeted radiation therapy, potentially slowing disease progression.
What could go wrong: This is a small early-phase trial with only 15 participants, so results may not apply broadly. The approach is experimental and may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.